According to Teva, the FDA has approved its QNASL HFA beclomethasone dipropionate nasal aerosol for the treatment of seasonal and perennial allergic rhinitis in adults and children 12 years of age and older, and the company plans to launch the product by the end of April 2012. QNASL is delivered by a pressurized nasal delivery device that includes a dose counter. Teva recently released additional positive Phase 3 results from several studies of the nasal aerosol.
“The approval of QNASL is a significant milestone for Teva Respiratory and represents our commitment to addressing the unmet needs of millions of Americans suffering from allergic rhinitis. We are committed to the development of new options for treatment of respiratory diseases that meet patients’ needs,” said Teva Global Respiratory Research and Development Senior VP Tushar Shah.
Co-founder of the Dallas Asthma and Allergy Center Gary N. Gross commented, “Given the number of people living with allergic rhinitis who are still seeking adequate relief, the availability of a new dry nasal aerosol is very welcome news. There are some patients with allergic rhinitis who report dissatisfaction with the currently available therapies. The approval of QNASL offers these patients a safe and effective treatment option with a new dry mode of delivery.”
Read the Teva press release.
